Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis
- 1 August 2005
- journal article
- other
- Published by SAGE Publications in Clinical Trials
- Vol. 2 (4) , 295-300
- https://doi.org/10.1191/1740774505cn100oa
Abstract
The Bayesian approach and several of its advantages in drug and medical device development are described. One advantage from the perspective of analysis is that it provides a methodology for synthesizing information. However, taking a Bayesian approach to designing clinical trials is potentially more valuable than using this approach in analyzing trial results. Bayesian methodology provides a mechanism for updating what is known as results accumulate during a trial. Such updating can be incorporated completely explicitly and prospectively. An important way in which the Bayesian approach can be used is in calculating the predictive probability distribution of future results on the basis of current results. I show how to exploit predictive distributions in adapting to results that accumulate during the course of a trial. Possible adaptations including decreasing or increasing sample size, dropping treatment arms, and modifying the randomization proportions to the various arms depending on the interim results. Consequences of taking a Bayesian approach to clinical trial design are efficiency, better treatment of patients in the trial, and greater precision regarding the primary endpoints. An example of the last of these is Bayesian modeling of the relationship between early and longer term endpoints. Such modeling also enables earlier decision making. Case studies 2 and 3 deal with trials that were shorter and smaller, respectively, because of such modeling.Keywords
This publication has 6 references indexed in Scilit:
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology, 2005
- Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture ModelBiometrics, 2004
- Bayesian Survival Analysis With Nonproportional HazardsJournal of the American Statistical Association, 2004
- The New Math of Clinical TrialsScience, 2004
- Bayesian Statistics and the Efficiency and Ethics of Clinical TrialsStatistical Science, 2004
- Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003